Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial
Document Type
Article
Publication Date
10-1-2024
Abstract
Objective To determine whether a chemokine receptor type 2 antagonist, DMX-200 (repagermanium), in combination with an angiotensin receptor blocker, candesartan, improves clinical outcomes in people with COVID-19. Design Prospective, multicentre, double-blind, placebo-controlled trial. Setting Ten acute care hospitals in India. Participants Adults <65 years old intended for hospital admission with moderate/severe COVID-19 disease (respiratory rate >= 24 breaths per minute or oxygen saturation <= 93% on room air). Intervention DMX-200 120 mg two times per day, or placebo, on background of titratable candesartan commencing at 4 mg two times per day, for 28 days. Main outcome measures The primary endpoint was COVID-19 disease severity on a modified WHO Clinical Progression Scale (WHO scale) on day 14. Secondary outcomes included the WHO scale at days 28, 60, 90 and 180; intensive care unit (ICU) admission, respiratory failure or death within 28 days; length of hospitalisation; and requirement for ventilatory support or dialysis. Results Between December 2021 and August 2022, 518 people were screened, with 49 randomised to DMX-200 or placebo on a background of candesartan. The study was terminated early due to recruitment barriers, including an external requirement to restrict enrolment to adults <65 years old, contributing to a 91% screen failure rate. The median WHO Clinical Progression Scale (WHO scale) score at day 14 for both groups was 1 (IQR 1-1), indicating most participants were discharged with no limitations on activities by this time. Formal comparison was not performed due to the small sample size. One participant receiving DMX-200 died of COVID-19 disease progression. No participants required ICU admission, ventilation or dialysis. Median length of hospitalisation in both groups was 6 days (IQR 6-7 days). WHO scale scores were similar at 28, 60, 90 and 180 days. Conclusion Due to recruitment barriers, the study was unable to determine whether DMX-200 improves clinical outcomes in people with COVID-19.
Divisions
medicinedept
Funders
Dimerix Bioscience Pty Ltd.,Australian Government Department of Industry, Innovation and Science,Royal Australian Society of Nephrology Jacquot Research Entry Scholarship,National Health & Medical Research Council (NHMRC) of Australia
Publication Title
BMJ Open
Volume
14
Issue
10
Publisher
BMJ Publishing Group
Publisher Location
BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND